Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Prevention Research

Abstract LB-427: Differential effects of resveratrol-induced SIRT1 in prostate cancer: A novel therapeutic target

Guiming Li, Rita Ghosh and Addanki P. Kumar
Guiming Li
1UTHSCSA, San Antonio, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita Ghosh
1UTHSCSA, San Antonio, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Addanki P. Kumar
1UTHSCSA, San Antonio, TX.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-LB-427 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Silence information regulator (SIRT1) is a Nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase that regulates various biological processes including cell survival, apoptosis, metabolism and aging. Given the role for calorie restriction (CR) in delaying the onset of aging and age-related disorders including cancers, efforts are under way to develop CR mimetics as therapeutic agents. Resveratrol, a CR mimetic activates SIRT1 and has been shown to extend life span. Further, resveratrol has been shown to prevent tumor development and cancer cell proliferation in a wide variety of models including prostate. However the precise role of SIRT1 in prostate cancer development and progression remains unexplored. Towards developing SIRT1 targeted preventive approaches, we conducted studies using human prostate cancer cell lines and a preclinical animal model that develops high grade prostatic intraepithelial neoplasia (HGPIN) in response to hormone stimulation. Our studies show that androgen independent prostate cancer cell lines (DU145 and PC-3) express higher levels of SIRT1 compared to non tumorigenic RWPE-1 consistent with the published results. Resveratrol-mediated inhibition of cell proliferation was associated with reduction in the levels of pAkt (Ser473 and Thr308), SIRT1and Cyclin D1 in PC-3 cells but not in DU145. Most interestingly we did not detect SIRT1 enzymatic activation following resveratrol treatment. Further pretreatment of prostate cancer cells with known pharmacological SIRT1 inhibitor (Nicotinamide) enhanced resveratrol mediated proliferation inhibition. Dietary intervention with increasing doses of resveratrol for 3 weeks showed no protective effect on the development of PIN lesions or chronic inflammation or atrophy in rats stimulated with hormones. Our studies show for the first time that (i) SIRT1 may not be a direct target of resveratrol; (ii) combination of resveratrol and SIRT1inhibitor may provide a new approach to prevent development and progression of prostate cancer. Supported by CA 137518 (APK).

Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-427.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-427: Differential effects of resveratrol-induced SIRT1 in prostate cancer: A novel therapeutic target
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract LB-427: Differential effects of resveratrol-induced SIRT1 in prostate cancer: A novel therapeutic target
Guiming Li, Rita Ghosh and Addanki P. Kumar
Cancer Res April 15 2010 (70) (8 Supplement) LB-427; DOI: 10.1158/1538-7445.AM10-LB-427

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-427: Differential effects of resveratrol-induced SIRT1 in prostate cancer: A novel therapeutic target
Guiming Li, Rita Ghosh and Addanki P. Kumar
Cancer Res April 15 2010 (70) (8 Supplement) LB-427; DOI: 10.1158/1538-7445.AM10-LB-427
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Prevention Research

  • Abstract LB-167: A novel metabolite of citrus tangeretin epigenetically inhibits the growth of human prostate cancer cells
  • Abstract LB-169: Targeted tumor prevention in Li-Fraumeni syndrome
  • Abstract LB-177: Chemopreventive effect of aged citrus peel (Chenpi) extracts against tumor initiator acetaminophen-induced hepatotoxicity through regulating Nrf2 pathway
Show more 3

Poster Presentations - Late-Breaking Abstracts

  • Abstract LB-335: Induction of Ribosomal Checkpoint Induced Senescence (RCIS) for the treatment of liver cancer
  • Abstract LB-266: DAXX promotes de novo lipogenesis in triple-negative breast cancer
  • Abstract LB-299: Glucose metabolism modulator HJC0152 differentially regulates glycolytic enzymes to suppress breast carcinogenesis
Show more 3

Late-Breaking Poster Presentations - Molecular Targets for Cancer Prevention

  • Abstract LB-428: Decursin inhibits advanced human prostate tumor xenograft growth involving antiproliferative and antiangiogenic mechanisms
  • Abstract LB-426: Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement